JUNIPER Disappoints But Lilly Continues With Abemaciclib In Different Combos, Cancers
Executive Summary
Lilly's top-line Phase III JUNIPER data for abemaciclib in KRAS-mutated advanced non-small cell lung cancer may have disappointed, but the big pharma has vowed to continue evaluating the agent in this and in other cancers, and in combination therapies.
You may also be interested in...
Lilly Plumbs Data's Depths To Differentiate CDK4/6 Inhibitor Verzenio
Lilly highlighted five prognostic factors at SABCS that may be linked to high Verzenio response. As the third CDK4/6 inhibitor on the US market, the company needs to differentiate its breast cancer drug from Pfizer's Ibrance and Novartis's Kisqali.
Lilly Hopes To Revitalize Its Cancer Brand With 'Foundational' Agents
While reporting 19% US sales growth for the quarter, Lilly also outlined a revised oncology R&D strategy and revealed that refiling the NDA for baricitinib may be delayed 18 months or more.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.